MyofascialPain

Myofascial pain syndrome (MPS) affects over 75% of the world's population and is one of the most overlooked causes of disability. This condition involves acute and chronic musculoskeletal pain that often includes a referred neuropathic component. The pain originates anywhere between the motor end plate and the fibrous muscle covering, involving microvasculature and neurotransmitters at the cellular level. Up to 85% of people will experience myofascial pain at least once in their lifetime, with prevalence ranging from 21% in general orthopedic patients to 93% in specialized pain centers.

Middle-aged, sedentary women appear to be at highest risk, while regular vigorous activity seems protective.

This comprehensive review examined the current understanding of myofascial pain syndrome, including its pathophysiology, diagnosis, and treatment options. The authors analyzed the mechanisms behind myofascial trigger points (MTrPs), which are the hallmark clinical sign of MPS. They reviewed diagnostic criteria including palpation techniques, physical examination findings, and ancillary tests. The review also examined treatment approaches ranging from conservative physical therapy to invasive procedures like trigger point injections and botulinum toxin therapy.

The pathophysiology involves increased acetylcholine release at motor end plates, leading to sustained muscle contraction, local ischemia, and release of inflammatory substances. This creates a positive feedback loop involving autonomic responses. Diagnosis relies primarily on clinical examination, with key criteria including palpable taut bands (65% frequency), limited range of motion (22%), patient pain recognition upon palpation (53%), local twitch response (44%), and predicted pain referral patterns (44%). Treatment effectiveness varies by approach: physical therapy and stretching remain the mainstay of treatment, manual therapy shows good evidence, dry needling demonstrates superiority over sham treatment for up to 4 weeks, and botulinum toxin A shows significant improvement in pain descriptors and muscle tension at 30 and 60 days post-treatment compared to placebo.

This review establishes that myofascial pain syndrome is a highly prevalent but often underdiagnosed condition requiring a multimodal treatment approach. Clinicians should prioritize physical therapy and manual techniques as first-line treatments, with trigger point injections and botulinum toxin reserved for refractory cases. The evidence supports dry needling as an effective intervention, though it may cause more post-treatment soreness than medication injections. For patients, this means that with proper diagnosis and treatment, myofascial pain can be effectively managed through a combination of exercise, manual therapy, and when necessary, minimally invasive procedures.

The key is early recognition and appropriate treatment to prevent chronic pain development.